Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR402663
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Administration
- Intravitreal
01
Overview
SAR402663 is an investigational drug developed by Sanofi for the treatment of neovascular (wet) age-related macular degeneration (nAMD). It is currently being evaluated in a Phase 1/2 clinical trial as a one-time intravitreal injection, with the aim of improving vision and reducing disease progression in adults with nAMD. The precise mechanism of action for SAR402663 has not been disclosed or remains undefined. The drug is considered a new molecular entity and represents a novel approach within eye disorder therapies. Clinical studies involve dose escalation and expansion phases, followed by long-term follow-up to assess safety and durability of effect.
- Other names
- SAR-402663SAR402663SAR 402663
Beyond the preview
Go deeper on SAR402663.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR402663.